tbuckley/cabot-search huggingface dataset:
Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B
Authors: Hye-Lin Kim, Gi-Ae Kim, Jae-A Park, Hye-Rim Kang, Eui-Kyung Lee, Young-Suk Lim
Journal: Gut (2020)

Objective The cost-effectiveness of antiviral treatment in adult immune-tolerant (IT) phase chronic hepatitis B (CHB) patients is uncertain. Design We designed a Markov model to compare expected costs and quality-adjusted life-years (QALYs) of starting antiviral treatment at IT-phase (‘treat-IT’) vs delaying the therapy until active hepatitis phase (‘untreat-IT’) in CHB patients over a 20-year horizon. A cohort of 10 000 non-cirrhotic 35-year-old patients in IT-phase CHB (hepatitis B e antigen-positive, mean serum hepatitis B virus (HBV) DNA levels 7.6 log 10 IU/mL, and normal alanine aminotransferase levels) was simulated. Input parameters were obtained from previous studies at Asan Medical Center, Korea. The incremental cost-effectiveness ratio (ICER) between the treat-IT and untreat-IT strategies was calculated. Results From a healthcare system perspective, the treat-IT strategy with entecavir or tenofovir had an ICER of US$16 516/QALY, with an annual hepatocellular carcinoma (HCC) incidence of 0.73% in the untreat-IT group. With the annual HCC risk ≥0.54%, the treat-IT strategy was cost-effective at a willingness-to-pay threshold of US$20 000/QALY. From a societal perspective considering productivity loss by premature death, the treat-IT strategy was extremely cost-effective, and was dominant (ICER &lt;0) if the HCC risk was ≥0.43%, suggesting that the treat-IT strategy incurs less costs than the untreat-IT strategy. The most influential parameters on cost-effectiveness of the treat-IT strategy were those related with HCC risk (HBV DNA levels, platelet counts and age) and drug cost. Conclusion Starting antiviral therapy in IT phase is cost-effective compared with delaying the treatment until the active hepatitis phase in CHB patients, especially with increasing HCC risk, decreasing drug costs and consideration of productivity loss.
15310 Treatment of acne with spironolactone: A retrospective review of 395 adult patients at Mayo Clinic, 2007-2017
Authors: Erin Roberts, Somaira Nowsheen, Mark D.P. Davis, Marian McEvoy, Catherine C. Newman, Julio C. Sartori-Valinotti, Gabriel Sciallis, Rochelle R. Torgerson, David A. Wetter
Journal: Journal of the American Academy of Dermatology (2020)
346P Occurence and risk factors of chemotherapy-induced neutropenia in patients with breast cancer: A hospital-based assessment in Indonesia
Authors: S.H. Hutajulu, Y.K. Sari, S. Oktariani, M.S. Hardiyanti, K.W. Taroeno-Hariadi, I. Purwanto, J. Kurnianda, A. Gusnanto
Journal: Annals of Oncology (2020)
Understanding Results of Trials in Heart Failure With Preserved Ejection Fraction: Remembering Forgotten Lessons and Enduring Principles⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.
Authors: Dalane W. Kitzman
Journal: Journal of the American College of Cardiology (2011)
AB0421 EFFECT OF BODY WEIGHT ON COMPLEMENT LEVELS IN SYSTEMIC LUPUS ERYTHEMATOSUS
Authors: L. Kondrateva, T. Popkova, E. Nasonov, A. Lila
Journal: Annals of the Rheumatic Diseases (2020)

Background: The complement system is a recognized biomarker for diagnosis or monitoring of disease activity in systemic lupus erythematosus (SLE) patients (pts). But on the other hand, it has been linked to insulin resistance and obesity in general population. Objectives: To find out whether overweight/obesity can modify C3 or C4 levels in SLE pts. Methods: A total of 92 SLE pts (83 women, 9 men, 39 [34;47] years old) were enrolled in the study. Median disease duration was 6[2;14] years, and SLE activity using SLEDAI-2K was 4[2;8]. SLE pts were treated with glucocorticoids (89%), hydroxychloroquine (78%), immunosuppressants (28%), biologics (10%). The overweight/obesity status was determined by World Health Organization criteria in patients with body mass index (BMI) ≥25kg/m2. Results: Overweight/obesity were established in 46% SLE pts. Overweight/obese SLE pts were older than pts with normal BMI (40[36;48] vs 37[31;44] years, р=0,02), and had lower SLEDAI-2K (3[2;6] vs 6[4;8], p&lt;0,01). Lower C3 concentrations were found in 36% overweight/obese pts vs 68% pts with normal weight (р&lt;0,01), decreased C4 levels - in 19% vs 30% pts (p=0,33), median C3 concentrations were 0,98[0,81;1,14] g/l vs 0,84[0,69;0;96] g/l (р&lt;0,01), and C4 levels were 0,15[0,10;0,19] g/l vs 0,12[0,09;0,16] g/l, respectively (p=0,03). C3 and C4 levels negatively correlated with SLEDAI-2K (r=-0,5, p&lt;0,01 for both), the effect was more strongly pronounced in patients with BMI≥25kg/m2 (r=-0,6, p&lt;0,01 for both) than in those with normal weight (r=-0,2, p=0,09 for C3, r=-0,3, p=0,04 for C4). Conclusion: Overweight/obesity status in SLE pts was associated with increased levels of complement proteins, therefore decreased C3 or C4 levels in patients with BMI≥25kg/m2 are more likely related to disease activity and, can potentially induce SLE flares. Disclosure of Interests: : None declared
Variation on a Theme: CMR as the “One-Stop Shop” for Risk Stratification After Infarction?⁎⁎Editorials published in JACC: Cardiovascular Imaging reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Imaging or the American College of Cardiology.
Authors: Katherine C. Wu
Journal: JACC. Cardiovascular imaging (2009)
SCENITH: A Flow Cytometry-Based Method to Functionally Profile Energy Metabolism with Single-Cell Resolution
Authors: Rafael J. Argüello, Alexis J. Combes, Remy Char, Julien-Paul Gigan, Ania I. Baaziz, Evens Bousiquot, Voahirana Camosseto, Bushra Samad, Jessica Tsui, Peter Yan, Sebastien Boissonneau, Dominique Figarella-Branger, Evelina Gatti, Emeline Tabouret, Matthew F. Krummel, Philippe Pierre
Journal: Cell Metabolism (2020)
Art in Endoscopy: “Bleeding art”
Authors: Jan F. Monkelbaan, Hendrikus J.M. Pullens
Journal: Endoscopy (2020)

On Christmas Eve, we performed a colonoscopy in a 50-year-old woman because of a change in bowel habits. Her medical history was unremarkable. She did not use any medication. Introduction to the cecum was uncomplicated. Upon withdrawal, a 15 mm pedunculated polyp was seen 30 cm from the anus, and it was decided to carry out polypectomy using a 2 cm loop with blend coagulation. The polypectomy went smoothly. However, as soon as the polyp came loose, the field of view was colored red by a fulminant spurting, arterial bleeding. For a moment our attention was drawn to the amazing spectacle that unfolded before us. The arterial vessel can be seen at bottom right with reflections of the endoscope light on the spraying blood. The bleeding was quickly stopped by injection of diluted adrenalin, followed by coagulation of the wound bed.
14066 Pharmacokinetics, safety and efficacy of ixekizumab in Chinese patients with plaque psoriasis: Results from a phase 1 single- and multiple-dose study
Authors: Feng Wang, Min Zheng, Xiang Chen, Chen Jisu, Kimberley Jackson, Fan Emily Yang, Christopher Payne, Jie Zheng
Journal: Journal of the American Academy of Dermatology (2020)
Abstract PO-031: MetMap: A map of metastatic potential of human cancer cell lines
Authors: Xin Jin, Zelalem Demere, Karthik Nair, Ahmed Ali, Gino B. Ferraro, Ted Natoli, Amy Deik, Lia Petronio, Andrew A. Tang, Cong Zhu, Li Wang, Danny Rosenberg, Vamsi Mangena, Jennifer Roth, Kwanghun Chung, Rakesh K. Jain, Clary B. Clish, Matthew G. Vander Heiden, Todd R. Golub
Journal: Cancer Research (2020)

Abstract Most deaths from cancer are explained by metastasis, and yet large-scale metastasis research has been impractical due to the complexity of in vivo models. Here, we introduce an in vivo barcoding strategy capable of determining the metastatic potential of human cancer cell lines in murine xenografts at scale. We validated the robustness, scalability and reproducibility of the method, and applied it to 500 cell lines spanning 21 solid cancer types. We created a first-generation Metastasis Map (MetMap) that reveals organ-specific patterns of metastasis and allows relating those patterns to clinical and genomic features. We demonstrated the utility of MetMap by exploring the molecular basis of breast cancers capable of metastasizing to the brain – a principal cause of death in these patients. We found that breast cancers capable of metastasizing to the brain had unexpected evidence of altered lipid metabolism. Perturbing lipid metabolism curbed brain metastasis development, suggesting a therapeutic strategy to combat the disease and demonstrating the utility of MetMap as a public resource to support metastasis research. Citation Format: Xin Jin, Zelalem Demere, Karthik Nair, Ahmed Ali, Gino B. Ferraro, Ted Natoli, Amy Deik, Lia Petronio, Andrew A. Tang, Cong Zhu, Li Wang, Danny Rosenberg, Vamsi Mangena, Jennifer Roth, Kwanghun Chung, Rakesh K. Jain, Clary B. Clish, Matthew G. Vander Heiden, Todd R. Golub. MetMap: A map of metastatic potential of human cancer cell lines [abstract]. In: Abstracts: AACR Special Virtual Conference on Epigenetics and Metabolism; October 15-16, 2020; 2020 Oct 15-16. Philadelphia (PA): AACR; Cancer Res 2020;80(23 Suppl):Abstract nr PO-031.
Pediatric Magnet Ingestions After Federal Rule Changes, 2009-2019
Authors: Michael R. Flaherty, Terry Buchmiller, Mark Vangel, Lois K. Lee
Journal: JAMA (2020)

This study describes trends in emergency department visits for ingestions by children of small neodymium magnets between 2009 and 2019, before, during, and after a 2014 Consumer Product Safety Commission rule restricting their sales.
OP0006 Distinct mechanisms of il-1 inhibition revealed by<i>in vitro</i>modelling of il-1 receptor accessory protein interactions with il-1/il-1 receptor complex
Authors: BC Varnum, A Witte, C Vezina, X Qian
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> IL-1 stimulates cellular responses by interacting with a heterodimeric receptor complex comprised of IL-1 receptor type I (IL-1RI) and IL-1 receptor accessory protein (IL-1RAcP). IL-1 first binds IL-1RI then IL-1RAcP is recruited to this complex. Inhibitors of IL-1 bioactivity may function through inhibiting any aspect of this complex formation. Understanding the mechanism of inhibition of specific inhibitors can shed light on the nature of the interfaces that define a high affinity site for IL-1RAcP binding. <h3>Objectives</h3> To model the interaction of IL-1 Receptor Accessory Protein with IL-1 bound IL-1 Receptor using purified recombinant proteins, and assess the mechanism of antagonism for IL-1 inhibitors. <h3>Methods</h3> The extracellular domain of IL-1RAcP was expressed and purified. The interaction of IL-1RAcP with IL-1RI, IL-1 and IL-1RI/IL-1 complex was explored in binding assays. Antibodies to IL-1 and IL-1RI have been used to investigate the roles of individual components of the complex. IL-1 bioassays have been developed to validate the <i>in vitro</i> findings. <h3>Results</h3> As expected, IL-1RAcP did not interact with either IL-1 or IL-1RI alone, even at high concentrations (100 nM), however, binding to complex was measured to be high affinity (~ 1 nM). Furthermore, purified IL-1RAcP enhanced binding of IL-1 to receptor. Antibodies to IL-1b have been identified which block binding of IL-1/IL-1RI to IL-1RAcP but fail to influence IL-1 binding to receptor. <h3>Conclusion</h3> The observation that anti-IL-1beta antibodies can selectively block binding of IL-1RAcP demonstrates a novel mechanism of IL-1 inhibition and supports the hypothesis that IL-1 makes direct contacts with IL-1RAcP. Since IL-1 does not demonstrate any measurable affinity for IL-1RAcP when not bound to IL-1RI, it is likely that additional elements of the binding site are comprised of IL-1RI residues. Future studies mapping the elements of IL-1RAcP involved in the contact points will further define the binding interface.
Inhibition of lncRNA MAAT Controls Multiple Types of Muscle Atrophy by cis- and trans-Regulatory Actions
Authors: Jin Li, Tingting Yang, Haifei Tang, Zhao Sha, Rui Chen, Lei Chen, Yan Yu, Glenn C. Rowe, Saumya Das, Junjie Xiao
Journal: Molecular Therapy (2020)

Muscle atrophy is associated with negative outcomes in a variety of diseases. Identification of a common therapeutic target would address a significant unmet clinical need. Here, we identify a long non-coding RNA (lncRNA) (muscle-atrophy-associated transcript, lncMAAT) as a common regulator of skeletal muscle atrophy. lncMAAT is downregulated in multiple types of muscle-atrophy models both in vivo (denervation, Angiotensin II [AngII], fasting, immobilization, and aging-induced muscle atrophy) and in vitro (AngII, H2O2, and tumor necrosis factor alpha [TNF-α]-induced muscle atrophy). Gain- and loss-of-function analysis both in vitro and in vivo reveals that downregulation of lncMAAT is sufficient to induce muscle atrophy, while overexpression of lncMAAT can ameliorate multiple types of muscle atrophy. Mechanistically, lncMAAT negatively regulates the transcription of miR-29b through SOX6 by a trans-regulatory module and increases the expression of the neighboring gene Mbnl1 by a cis-regulatory module. Therefore, overexpression of lncMAAT may represent a promising therapy for muscle atrophy induced by different stimuli.
14152 Patient-reported outcomes in a head-to-head, randomized, double-blinded clinical trial of ixekizumab and guselkumab in patients with moderate to severe plaque psoriasis
Authors: Andrew Blauvelt, Catherine Maari, Alice B. Gottlieb, Hany ElMaraghy, So Young, Renata Gontijo Lima, Russel Burge, Park Gaia Gallo, Lisa Renda, Jerry Bagel
Journal: Journal of the American Academy of Dermatology (2020)
259O Treatment patterns and outcomes in older patients with mantle cell lymphoma in an Asian population
Authors: X. Yang, L.P. Khoo, E.W.Y. Chang, V.S. Yang, E.Y.L. Poon, N. Somasundaram, M. Farid, T.P.L. Tang, M. Tao, S.T. Lim, J.Y. Chan
Journal: Annals of Oncology (2020)
15447 Effectiveness and safety of ustekinumab using intravenous induction in patients with hidradenitis suppurativa
Authors: Eva María Sánchez Martínez, Marina Sáez Belló, Ramón García Ruiz, Lya Magdalena Moneva-Leniz, Almudena Mateu Puchades
Journal: Journal of the American Academy of Dermatology (2020)
Achieving Optimal Population Cardiovascular Health Requires an Interdisciplinary Team and a Learning Healthcare System: A Scientific Statement From the American Heart Association
Authors: Randi E. Foraker, Catherine P. Benziger, Bailey M. DeBarmore, Crystal W. Cené, Fleetwood Loustalot, Yosef Khan, Cheryl A.M. Anderson, Véronique L. Roger
Journal: Circulation (2020)

Population cardiovascular health, or improving cardiovascular health among patients and the population at large, requires a redoubling of primordial and primary prevention efforts as declines in cardiovascular disease mortality have decelerated over the past decade. Great potential exists for healthcare systems-based approaches to aid in reversing these trends. A learning healthcare system, in which population cardiovascular health metrics are measured, evaluated, intervened on, and re-evaluated, can serve as a model for developing the evidence base for developing, deploying, and disseminating interventions. This scientific statement on optimizing population cardiovascular health summarizes the current evidence for such an approach; reviews contemporary sources for relevant performance and clinical metrics; highlights the role of implementation science strategies; and advocates for an interdisciplinary team approach to enhance the impact of this work.
Cardiovascular Magnetic Resonance in Clinically Suspected Cardiac Amyloidosis: Diagnostic Value of a Typical Pattern of Late Gadolinium Enhancement⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.
Authors: Louise E.J. Thomson
Journal: Journal of the American College of Cardiology (2008)
Transdermal microneedles for the programmable burst release of multiple vaccine payloads
Authors: Khanh T. M. Tran, Tyler D. Gavitt, Nicholas J. Farrell, Eli J. Curry, Arlind B. Mara, Avi Patel, Lindsey Brown, Shawn Kilpatrick, Roxana Piotrowska, Neha Mishra, Steven M. Szczepanek, Thanh D. Nguyen
Journal: Nature Biomedical Engineering (2020)
Polyunsaturated Fatty Acids in Heart Failure: Should We Give More and Give Earlier?⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.
Authors: W.H. Wilson Tang, Michael A. Samara
Journal: Journal of the American College of Cardiology (2011)
113TiP Prospective observational study monitoring circulating tumour DNA in resectable colorectal cancer patients undergoing radical surgery: GALAXY study in CIRCULATE-Japan
Authors: H. Yukami, M. Saori, D. Kotani, E. Oki, H. Taniguchi, Y. Nakamura, T. Kato, I. Takemasa, T. Yamanaka, H. Shirasu, K. Sawada, H. Ebi, A. Aleshin, P. Billings, M. Mori, T. Yoshino
Journal: Annals of Oncology (2020)
Maculopapular eruptions and vesicles on the limbs and buttocks
Authors: Wu Guo, Ge Qian
Journal: BMJ (2020)

A 3 year old girl presented to the dermatology department with three days of a progressively worsening rash and swelling of the extremities, and two days of a persisting fever of around 38.1°C. Initially her hands were swollen and itchy, then dome-shaped maculopapular eruptions developed and rapidly progressed to involve both elbows (fig 1). She also had multiple erythematous papules on the lower limbs and buttocks, and vesicles were present across the buttocks and ankles (fig 2). A few vesicles with crusting were also seen on her upper and lower lips.



Fig 1 
Multiple dome-shaped maculopapular eruptions on hands





Fig 2 
Scattered vesicles on the buttocks



She had a mild non-productive cough, malaise, and an …
Nestin+/CD31+ cells in the hypoxic perivascular niche regulate glioblastoma chemoresistance by upregulating JAG1 and DLL4
Authors: Zong-Qing Zheng, Jin-Tao Chen, Ming-Cheng Zheng, Li-Juan Yang, Jun-Ming Wang, Quan-Li Liu, Lu-Fei Chen, Zu-Cheng Ye, Jin-Ming Lin, Zhi-Xiong Lin
Journal: Neuro-Oncology (2020)

Failure of glioblastoma (GBM) therapy is often ascribed to different types of glioblastoma stem-like cell (GSLC) niche; in particular, a hypoxic perivascular niche (HPVN) is involved in GBM progression. However, the cells responsible for HPVNs remain unclear.Immunostaining was performed to determine the cells involved in HPVNs. A hypoxic chamber and 3-dimensional (3D) microfluidic chips were designed to simulate a HPVN based on the pathological features of GBM. The phenotype of GSLCs was evaluated by fluorescence scanning in real time and proliferation and apoptotic assays. The expression of JAG1, DLL4, and Hes1 was determined by immunostaining, ELISA, Western blotting, and quantitative PCR. Their clinical prognostic significance in GBM HPVNs and total tumor tissues were verified by clinical data and The Cancer Genome Atlas databases.Nestin+/CD31+ cells and pericytes constitute the major part of microvessels in the HPVN, and the high ratio of nestin+/CD31+ cells rather than pericytes are responsible for the poor prognosis of GBM. A more real HPVN was simulated by a hypoxic coculture system in vitro, which consisted of 3D microfluidic chips and a hypoxic chamber. Nestin+/CD31+ cells in the HPVN were derived from GSLC transdifferentiation and promoted GSLC chemoresistance by providing more JAG1 and DLL4 to induce downstream Hes1 overexpression. Poor GBM prognosis correlated with Hes1 expression of tumor cells in the GBM HPVN, and not with total Hes1 expression in GBM tissues.These results highlight the critical role of nestin+/CD31+ cells in HPVNs that acts in GBM chemoresistance and reveal the distinctive prognostic value of these molecular markers in HPVNs.
Targeting G protein-coupled receptors for the treatment of chronic pain in the digestive system
Authors: Lena Gottesman-Katz, Rocco Latorre, Stephen Vanner, Brian L Schmidt, Nigel W Bunnett
Journal: Gut (2020)

Chronic pain is a hallmark of functional disorders, inflammatory diseases and cancer of the digestive system. The mechanisms that initiate and sustain chronic pain are incompletely understood, and available therapies are inadequate. This review highlights recent advances in the structure and function of pronociceptive and antinociceptive G protein-coupled receptors (GPCRs) that provide insights into the mechanisms and treatment of chronic pain. This knowledge, derived from studies of somatic pain, can guide research into visceral pain. Mediators from injured tissues transiently activate GPCRs at the plasma membrane of neurons, leading to sensitisation of ion channels and acute hyperexcitability and nociception. Sustained agonist release evokes GPCR redistribution to endosomes, where persistent signalling regulates activity of channels and genes that control chronic hyperexcitability and nociception. Endosomally targeted GPCR antagonists provide superior pain relief in preclinical models. Biased agonists stabilise GPCR conformations that favour signalling of beneficial actions at the expense of detrimental side effects. Biased agonists of µ-opioid receptors (MOPrs) can provide analgesia without addiction, respiratory depression and constipation. Opioids that preferentially bind to MOPrs in the acidic microenvironment of diseased tissues produce analgesia without side effects. Allosteric modulators of GPCRs fine-tune actions of endogenous ligands, offering the prospect of refined pain control. GPCR dimers might function as distinct therapeutic targets for nociception. The discovery that GPCRs that control itch also mediate irritant sensation in the colon has revealed new targets. A deeper understanding of GPCR structure and function in different microenvironments offers the potential of developing superior treatments for GI pain.
Use of the Ovesco remOVE DC cutter to trim a metal biliary stent with excess length in the duodenum allowing biliary access for ERCP
Authors: Tareq El Menabawey, Harry Martin, Constantinos Parisinos, Michael Chapman
Journal: Endoscopy (2020)

A 78-year-old woman presented with jaundice and cholangitis, having presented 3 years previously with jaundice and hilar stricturing to a hospital elsewhere. The previous episode had been managed as a suspected cholangiocarcinoma with percutaneous transhepatic drainage followed by the insertion of overlapping self-expanding metal stents (SEMSs) extending from the hilum into the duodenum. The stricture had not progressed during 3 years of follow-up and we assessed this to be a benign post-cholecystectomy stricture.
314P Comprehensive microbial signatures and genomic profiling in tumour samples using next generation sequencing
Authors: M.Q. Yee, Y.L. Kok, P. Ariyaratne, Y. Yu, O. Scully, D. Tay, C. Tang, T. Ong, H. Suhardi, K.K.M. Aye, A.W. Kyaw, E. Wee, C. Lee
Journal: Annals of Oncology (2020)
Association of Insulin Resistance With Depression Severity and Remission Status
Authors: Kathleen T. Watson, Julia F. Simard, Victor W. Henderson, Lexi Nutkiewicz, Femke Lamers, Natalie Rasgon, Brenda Penninx
Journal: JAMA Psychiatry (2020)

This study investigates whether insulin resistance was positively associated with the presence, severity, or chronicity of major depression.
215P Analysis of spatial heterogeneity of responses in metastatic sites with nivolumab in renal cell carcinoma
Authors: V.P.B. Koyyala, A. Jajodia, L. Beer, D.C. Doval, V. Talwar, V. Goel, U. Batra, S. Goyal, A. Gupta, A. Chaturvedi, H. Prosch, S. Joga, K.R. Domadia, P. Medisetty, B. Amrith, M. La Mantia, S. Pasricha, A. Russo, A. Mehta
Journal: Annals of Oncology (2020)